24 results on '"Bystryn, Jean-Claude"'
Search Results
2. Increasing ratio of thin to thick melanoma lesions: pathogenesis and early detection of this cancer.
- Author
-
Bystryn JC
- Subjects
- Humans, Melanoma pathology, Melanoma surgery, Skin Neoplasms pathology, Skin Neoplasms surgery, Melanoma diagnosis, Skin Neoplasms diagnosis
- Published
- 2007
- Full Text
- View/download PDF
3. Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?
- Author
-
Reynolds SR, Vergilis IJ, Szarek M, Ferrone S, and Bystryn JC
- Subjects
- Adolescent, Adult, Aged, Cytoplasm, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Melanoma drug therapy, Melanoma pathology, Melanoma surgery, Middle Aged, Multivariate Analysis, Neoplasm Staging, Odds Ratio, Predictive Value of Tests, Skin Neoplasms drug therapy, Skin Neoplasms pathology, Skin Neoplasms surgery, Antigens, Neoplasm blood, Biomarkers, Tumor blood, Cancer Vaccines therapeutic use, Melanoma immunology, Skin Neoplasms immunology
- Abstract
Simple, noninvasive methods are needed to follow effectiveness of new treatments in patients with melanoma. In our study, we examined cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in melanoma patients during immunotherapy. Sera of 117 patients were assayed for CYT-MAA by double-sandwich ELISA before and during treatment with a polyvalent, shed antigen, melanoma vaccine. Vaccine-treated patients included 30 with American Joint Committee on Cancer (AJCC) stage IIb or IIIa, 30 with stage IIc, IIIb or IIIc, 30 with resected stage IV and 27 with measurable stage IV disease. Prior to vaccine therapy, 63% of patients had elevated serum CYT-MAA with high levels of antigen in all disease stages. After initiation of therapy, the level declined in more than 90% of the positive patients and fell below the positive cut-off in 56% of these patients within 5 months. By contrast, there was no decline in CYT-MAA serum level in 11 patients who served as untreated controls with melanoma. Multivariate analysis of the treated patients using accelerated failure time Weibull models adjusted for stage and age showed that patients whose CYT-MAA serum level remained elevated during treatment were approximately 3 times more likely to recur or progress than patients who were consistently below the positive cut-off (hazard ratio = 3.42, 95% CI [1.38, 8.47], p = 0.0079). Measurement of CYT-MAA serum level appears to show potential as an early marker of prognosis in patients with stages IIb to IV melanoma. Measurement of CYT-MAA serum level during therapy could provide an intermediate marker of response in these patients.
- Published
- 2006
- Full Text
- View/download PDF
4. Emerging melanoma vaccines.
- Author
-
Bystryn JC and Rudolph JL
- Subjects
- Animals, Clinical Trials as Topic statistics & numerical data, Humans, Melanoma immunology, Melanoma prevention & control, Skin Neoplasms immunology, Skin Neoplasms prevention & control, Cancer Vaccines therapeutic use, Drug Industry trends, Drugs, Investigational therapeutic use, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
No satisfactory treatment currently exists for melanoma once it has spread beyond its original site. At present, the only FDA-approved treatment for advanced melanoma is IFN-alpha2b. Vaccines are an experimental therapy intended to stimulate the immune system to react more strongly against patients' own melanoma cells, thereby destroying the tumour or slowing its progression. Unfortunately, the exact tumour antigens that can stimulate an effective tumour-protective response in humans remain unknown. The approach that is increasingly followed to circumvent this problem is to prepare polyvalent vaccines containing a variety of melanoma antigens, as the greater the number of antigens in a vaccine, the greater the chance it will contain the correct antigen(s) to stimulate an antitumour response. Two recent randomised trials suggest that this approach results in vaccines that can be clinically effective. One is a double-blind, placebo-controlled trial of a polyvalent, shed antigen melanoma vaccine developed by Bystryn and licenced to NeoVac; the other is a larger randomised trial of Melacine (Corixa Corp.), a vaccine prepared from the lysate of two melanoma cell lines adjuvanted with Detox, which was developed by Mitchell and commercialized by Corixa. In both cases, tumour progression was delayed in the vaccine-treated patients, although in the latter trial, this was only observed in patients with certain human leukocyte antigen phenotypes. Several other vaccines are currently in Phase III trials, but the results of these trials are still pending. The major issues that need to be addressed are designing more effective melanoma vaccines with a mix of melanoma-associated antigens that can stimulate clinically beneficial antitumour immune responses, and finding an adjuvant that can safely, easily and powerfully boost the frequency and magnitude of these responses.
- Published
- 2005
- Full Text
- View/download PDF
5. Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice.
- Author
-
Johnston D and Bystryn JC
- Subjects
- Animals, Blotting, Western, Female, Humans, Immunoglobulin G analysis, Mice, Mice, Inbred BALB C, Molecular Weight, Vaccines, Combined, Antibodies, Neoplasm blood, Antigens, Neoplasm immunology, Cancer Vaccines immunology, Melanoma immunology, Skin Neoplasms immunology
- Abstract
In this study, a human melanoma vaccine induced antibody responses in mice that varied significantly from animal to animal. BALB/c mice were immunized to a xenogenic human polyvalent melanoma vaccine that has been used in phase II clinical trials in over 600 patients. Mice were bled biweekly for up to 6 weeks to measure antibody responses. IgG antibody responses to the melanoma vaccine components were detectable within 2 weeks but were much stronger at 4 and 6 weeks. When the pooled sera were further analyzed by Western blot, a complex pattern of antigens was detected. When individual sera from identically immunized mice were assayed by Western blot, a consistent, reproducible pattern of antigen recognition was not seen. Rather, we found significantly different antibody responses among the mice. Both the intensity of antibody responses and the pattern of antigens recognized varied from animal to animal. Although there appeared to be immunodominant antigens that produced antibody responses in most mice, no single antigen induced antibody responses in all mice. These results demonstrate that polyvalent vaccines induce heterogeneous antibody responses in mice treated identically. Analysis of the response of selected melanoma patients immunized to the same vaccine revealed similar antibody responses to the antigens in the melanoma vaccine. Heterogeneity may hamper interpretation of vaccine immunogenicity and relevant tumor antigens in humans.
- Published
- 2005
- Full Text
- View/download PDF
6. Melanoma vaccines: what we know so far.
- Author
-
Bystryn JC and Reynolds SR
- Subjects
- Antibody Formation, Antigens, Neoplasm, Biomarkers, Tumor, Clinical Trials as Topic, Disease-Free Survival, Humans, Melanoma-Specific Antigens, T-Lymphocytes, Cancer Vaccines, Melanoma immunology, Melanoma therapy, Neoplasm Proteins immunology, Skin Neoplasms immunology, Skin Neoplasms therapy
- Abstract
Vaccines are a promising but still experimental treatment for melanoma. They are intended to stimulate immune responses against melanoma and by so doing, increase resistance against and slow the progression of this cancer. Key requirements for vaccines to be effective are that they contain antigens that can stimulate tumor-protective immune responses and that some of these antigens are present on the tumor to be treated. Unfortunately, these antigens are still not known. To circumvent this problem, polyvalent vaccines can be constructed containing a broad array of melanoma-associated antigens. Several strategies are available to construct such polyvalent vaccines; each has advantages and disadvantages. Clinical trials have shown that vaccines are safe to use and have much less toxicity than current therapy for melanoma. Vaccines can stimulate both antibody and T-cell responses against melanoma, with the type of response induced, its frequency, and its magnitude depending on the vaccine and the adjuvant agent used. A growing body of evidence suggests that vaccines can be clinically effective. This evidence includes correlations between vaccine-induced antibody or T-cell responses and improved clinical outcome, clearance of melanoma markers from the circulation, improved survival compared to historical controls, and most convincingly, two randomized trials in which the recurrence-free survival of vaccine-treated patients was significantly longer than that of control groups.
- Published
- 2005
7. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma.
- Author
-
Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A, and Bystryn JC
- Subjects
- Adolescent, Adult, Aged, Disease-Free Survival, Female, Humans, Immunotherapy methods, Male, Melanoma metabolism, Melanoma mortality, Middle Aged, Prognosis, Reverse Transcriptase Polymerase Chain Reaction, Time Factors, Treatment Outcome, Biomarkers, Tumor, Melanoma blood, Melanoma therapy, Neoplastic Cells, Circulating metabolism
- Abstract
Purpose: Melanoma cells can be found in the circulation of patients with melanoma. The following study was conducted to examine whether changes in their presence could provide an early marker of response to therapy., Experimental Design: We measured the presence of several markers of melanoma cells in the peripheral blood of 118 patients with resected stage IIb, III, or IV melanoma before and after immunotherapy with a polyvalent, shed antigen, melanoma vaccine using reverse transcription-PCR assays for tyrosinase, gp100, MART-1, and MAGE-3. Assays were conducted at baseline and after 3, 5, and 11 months of therapy., Results: Overall, 47% of patients were positive for at least one marker during the study. Before vaccine treatment, circulating melanoma cell markers were present in 23% of patients. After 5 and 7 months of vaccine therapy, the proportion of patients with circulating markers decreased by 27% and 55%, respectively (P for trend = 0.02). The recurrence-free survival of patients whose melanoma cell markers disappeared during vaccine treatment was significantly longer than that of patients in whom they increased, i.e., the percentage of patients who were recurrence free at 1 year was 80% versus 58% (P = 0.03)., Conclusions: Therapy with a polyvalent melanoma vaccine was associated with clearance of melanoma cell markers from the circulation, and the clearance was associated with an improved prognosis. These findings suggest that the sequential assay of tumor cells in the circulation by reverse transcription-PCR may provide an early indication of the effectiveness of cancer therapy.
- Published
- 2003
8. Improved identification of potentially dangerous pigmented skin lesions by computerized image analysis.
- Author
-
Jamora MJ, Wainwright BD, Meehan SA, and Bystryn JC
- Subjects
- Biopsy, Needle, Cohort Studies, Diagnosis, Differential, Dysplastic Nevus Syndrome diagnosis, Dysplastic Nevus Syndrome surgery, Female, Humans, Immunohistochemistry, Male, Melanoma diagnosis, Melanoma surgery, Neoplasm Staging, Nevus, Pigmented diagnosis, Nevus, Pigmented surgery, Sensitivity and Specificity, Skin Neoplasms diagnosis, Skin Neoplasms surgery, Diagnosis, Computer-Assisted methods, Dysplastic Nevus Syndrome pathology, Image Processing, Computer-Assisted, Melanoma pathology, Nevus, Pigmented pathology, Skin Neoplasms pathology
- Abstract
Background: Melanoma is completely curable if resected early. Unfortunately, early melanoma can be difficult to differentiate from other pigmented lesions. Computerized image analysis instruments have now been developed to assist in determining whether a pigmented lesion is potentially dangerous and requires biopsy. To evaluate whether one such instrument can improve the management of pigmented lesions, we obtained biopsy specimens from 52 pigmented lesions that appeared clinically benign to an experienced dermatologist but were suspicious by image analysis., Observation: Histologically, 9 (17%) of the lesions that were removed based solely on computer recommendation were potentially dangerous and should have been removed. These included 1 malignant melanoma in situ and 8 dysplastic nevi with moderate to severe cytologic atypia., Conclusion: The results of the present study indicate that computerized image analysis can improve the evaluation of pigmented skin lesions by identifying clinically unsuspicious, but potentially dangerous, lesions that might have otherwise have been neglected.
- Published
- 2003
- Full Text
- View/download PDF
9. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
- Author
-
Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, and Bystryn JC
- Subjects
- Adult, Aged, Disease-Free Survival, Female, Histocompatibility Testing, Humans, Male, Melanoma pathology, Melanoma surgery, Middle Aged, Multivariate Analysis, Neoplasm Staging, Proportional Hazards Models, Antigens, Neoplasm immunology, CD8-Positive T-Lymphocytes immunology, Cancer Vaccines immunology, Cancer Vaccines therapeutic use, Lymphocyte Activation, Melanoma immunology, Melanoma therapy, Neoplasm Proteins immunology
- Abstract
Purpose: Vaccine-induced antitumor CD8+ T-cell responses are believed to play an important role in increasing resistance to melanoma. The following study was conducted to examine whether these responses are associated with improved clinical outcome in melanoma vaccine-treated patients., Experimental Design: We measured CD8+ T-cell responses to gp100, MART-1, MAGE-3, and tyrosinase by enzyme-linked immunospot assay in peripheral blood of 131 HLA-A*01- or HLA-A*02-positive melanoma patients before and after immunization to a polyvalent, shed antigen, melanoma vaccine, and correlated the results with clinical outcome., Results: Fifty-six percent of patients had a vaccine-induced CD8+ T-cell response to at least one of the four antigens. Recurrences were significantly reduced in patients with vaccine-induced responses to MAGE-3 (hazard ratio, 0.42; 95% confidence interval, 0.18-0.99; P = 0.03) by the Cox proportional hazard model but were unrelated to responses to the other three antigens. Patients with a preexisting response to any of the four antigens were significantly more likely to have a further vaccine-boosted response to that same antigen (P < 0.0001-0.036)., Conclusions: There was a correlation between vaccine-induced CD8+ T-cell responses to melanoma-associated antigens and improved clinical outcome, but the correlation depended on the antigen against which the response is directed. The only significant correlation was with responses to MAGE-3.
- Published
- 2003
10. Vaccines for melanoma.
- Author
-
Bystryn JC
- Subjects
- Biopsy, Needle, Cancer Vaccines pharmacology, Clinical Trials as Topic, Female, Humans, Male, Melanoma mortality, Neoplasm Staging, Prognosis, Risk Assessment, Skin Neoplasms mortality, Survival Analysis, Treatment Outcome, Cancer Vaccines administration & dosage, Immunotherapy methods, Melanoma pathology, Melanoma therapy, Skin Neoplasms pathology, Skin Neoplasms therapy
- Abstract
Melanoma vaccines are now an accepted but still experimental treatment for patients who have been rendered clinically free of disease by surgical resection but are at high risk of recurrence and in selected patients with advanced but still limited disease. In general, there seems to be a correlation between the ability of melanoma vaccines to stimulate antimelanoma cellular or antibody immune responses and improved clinical outcome. Accordingly, a number of strategies are now being pursued to improve the clinical effectiveness of this first generation of vaccines by improving their ability to stimulate antimelanoma immunity. To establish the true effectiveness of vaccines in the treatment of malignant melanoma, several large, prospectively randomized phase III studies are currently being conducted.
- Published
- 2002
- Full Text
- View/download PDF
11. Can nondermatologists really recognize potentially dangerous skin lesions as well as dermatologists?
- Author
-
Bystryn JC
- Subjects
- Humans, Medicine, Melanoma diagnosis, Prognosis, Sensitivity and Specificity, Skin Neoplasms diagnosis, Specialization, Time Factors, Clinical Competence, Dermatology methods, Melanoma pathology, Skin Neoplasms pathology
- Published
- 2002
- Full Text
- View/download PDF
12. Tumor vaccines
- Author
-
Bystryn, Jean-Claude
- Published
- 1990
- Full Text
- View/download PDF
13. Correspondence.
- Author
-
Grob, Jean Jacques, Richard, Marie Aleth, Bystryn, Jean-Claude, Akman, Ayse, Skrabs, Cathrin Constanze, Cramer, Stewart F., Bogdan, Inja, Burg, Gunther, Boni, Roland, Dereure, Oliver, Bessis, Didier, Guillot, Bernard, Guilhou, Jean-Jacques, Vincent, Marie-Claire, Cosséé, Mireille, Vabres, Pierre, Stewart, Fiona, Bonneau, Dominique, and Calvas, Patrick
- Subjects
DERMATOLOGY ,MELANOMA ,ENZYME-linked immunosorbent assay ,IMMUNOGLOBULINS - Abstract
Presents commentaries on various studies pertaining to dermatology, featured in the September 2002 issue of the 'Archives of Dermatology.' Debate over diagnostic accuracy in melanoma; Limitations in enzyme-linked immunosorbent assays for antibodies against desmogleins 1 and 3 in patients with pemphigus; Molecular and cellular pathogenesis of spitz nevi.
- Published
- 2002
14. REPRODUCIBILITY OF THE IMMUNOFLUORESCENT TEST FOR ANTIMELANOMA ANTIBODIES.
- Author
-
Abel, Elizabeth A. and Bystryn, Jean-Claude
- Subjects
- *
REPRODUCTION , *IMMUNOFLUORESCENCE , *MELANOMA , *IMMUNOGLOBULINS , *BLOOD proteins , *SEX (Biology) - Abstract
The reproducibility of the indirect immunofluorescent test for antibodies to human malignant melanoma cytoplasmic antigens was investigated by testing panels of melanoma and normal sera against cells of each of several different melanomas. Tests were performed in replicate, read blindly by two observers, and repeated on different days. Different observers agreed in the interpretation of replicate assays in approximately 80 to 90% of cases. Variability increased considerably when assays were repeated on different days or when different melanomas were used as substrate. Under these circumstances, similar results were obtained in as few as 21% of test. Thus, the results of the indirect immunofluorescent test for melanoma cytoplasmic antibodies must, at the present time be interpreted with great caution. [ABSTRACT FROM AUTHOR]
- Published
- 1976
- Full Text
- View/download PDF
15. EPIDERMAL CYTOPLASMIC ANTIBODIES: INCIDENCE AND TYPE IN NORMAL PERSONS ADN PATIENTS WITH MELANOMA.
- Author
-
Abel, Elizabeth A. and Bystryn, Jean-Claude
- Subjects
- *
IMMUNOGLOBULINS , *CYTOPLASM , *SKIN diseases , *MELANOMA , *CELL differentiation , *EPIDERMIS - Abstract
Antibodies to epidermal cytoplasmic antigens were present in 25 to 34% of 32 normal persons and in 34 to 50% of 53 patients with melanoma. There were at least two different types of cytoplasmic antibodies. The most common reacted to cytoplasmic antigens present only in the upper layers of the epidermis. This type of antibody occurred with equal frequency in patients with melanoma and in normal persons. The increased incidence of cytoplasmic antibodies in melanoma was due to antibodies to cytoplasmic antigens present throughout the epidermis. These antibodies were 2½ times more common in patients with melanoma than in normal persons. The presence of different cytoplasmic antigens in distinct strata of the epidermis suggests they result from epidermal cell differentiation. The epidermal cytoplasmic antigens present throughout the epidermis appear to partially cross-react with cytoplasmic antigens in melanoma cells. [ABSTRACT FROM AUTHOR]
- Published
- 1976
- Full Text
- View/download PDF
16. GROWTH AND IMMUNOGENICITY OF MURINE B-16 MELANOMA.
- Author
-
Bystryn, Jean-Claude, Bart, Robert S., Livingston, Phillip, and Kopf, Alfred W.
- Subjects
- *
MELANOMA , *CELLS , *GROWTH , *IMMUNIZATION , *ANTIGENS , *ADENOCARCINOMA , *MAMMARY glands , *MICE - Abstract
The growth of fresh and I issue cultured B-16 malignant melanoma cells in C57BL/6 mice was quantitated, using as parameters the latent time to tumor appearance, tumor incidence, and mortality rate. The tumor was antigenic, as evidenced by the appearance of humoral antibodies to melanoma-associated antigens during the natural growth of this tumor and by the induction of resistance to lethal doses of tumor by immunization with repeated injections of irradiated, or sublethal doses of viable, melanoma cells. This immunity was not entirely specific, since mice immunized to B-16 melanoma were slightly resistant to challenge with BW10232 mammary adenocarcinoma and, conversely, mice immunized to mammary adenocarcinoma were slightly resistant to melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 1974
- Full Text
- View/download PDF
17. The Immunobiology of Human Malignant Melanoma.
- Author
-
Bystryn, Jean-Claude
- Subjects
MELANOMA ,IMMUNOREGULATION ,IMMUNE recognition ,CANCER cells ,APOPTOSIS ,NEUROENDOCRINE tumors ,IMMUNOMODULATORS - Abstract
Reports on issues related to the immunobiology of human malignant melanoma by researchers from New York City. Efforts of the researchers to devise a system that would permit manipulations to the immune system to get rid of malignant cells; Factors that influence the development of malignant melanoma; Mechanisms of tumor escape from immune destruction; Evidence showing that host immune factors can retard tumor growth in man.
- Published
- 1980
- Full Text
- View/download PDF
18. Antimelanoma Antibodies in Swine With Spontaneously Regressing Melanoma.
- Author
-
CUI, JIAN, CHEN, DUNLU, MISFELDT, MICHAEL L., SWINFARD, RONALD W., and BYSTRYN, JEAN-CLAUDE
- Abstract
Sinclair swine provide a unique model for studying mechanisms of tumor regression because they are born with melanomas that spontaneously regress approximately 10 weeks after birth. To examine whether an antitumor immune response is present in these animals, and, if so, to study its relation to tumor regression, 38 sera specimens collected at different times from 13 swine born with melanomas were tested for melanoma antibodies by immunoprecipitation and SDS-PAGE analysis of
125 I labelled swine melanoma macromolecules. Antibodies to melanoma were present in 13 (100%) of the swine versus 1 of 3 control swine. The antibodies were directed to antigens of approximately 45, 68-75, or 100 kDa. These antigens were also expressed on human melanomas and normal melanocytes but on only one of five unrelated tumors. The incidence and level of these antibodies increased with time. Antibodies to the 45, 68-75, and 100 kDa antigens were present in 36%, 55%, and 9%, respectively, of sera collected prior to 7 weeks of age, but in 80%, 100%, and 37% of sera collected between 7 and 20 weeks ( P<0.05). The rise in melanoma antibodies usually preceded or appeared together with tumor regression and loss of pigmentation. These findings indicate that Sinclair swine with melanomas have antibodies to antigens preferentially expressed on pigment cells, and support the hypothesis that the regression phenomenon and the vitiligo-like skin depigmentation result from immune responses to common antigens shared by normal and malignant swine pigment cells. [ABSTRACT FROM AUTHOR]- Published
- 1995
- Full Text
- View/download PDF
19. Characterization of Vitiligo Antigens.
- Author
-
CUI, JIAN, ARITA, YUKO, and BYSTRYN, JEAN-CLAUDE
- Abstract
Patients with vitiligo have circulating antibodies directed in part to pigment cell antigens with MWs of approximately 90, 75, and 40-45 kDs. These antigens are denominated VIT 90, VIT 75, and VIT 40, respectively. To further characterize these 'vitiligo' antigens, we examined their relation to antigens defined by a panel of 25 monoclonal antibodies (moab) to pigment cell antigens. We found by immunoprecipitation and SDS-PAGE analysis of
125 I labelled, detergent soluble, human melanocyte macromolecules, that 24 (83%) of 29 patients with vitiligo had antibodies to one or more vitiligo antigens vs. 2 (7%) of 28 control individuals. Seventeen of the 25 moabs did not react with any labelled antigen in the same lysate. Of the remaining eight moabs, only four precipitated an antigen that co-migrated with one of the vitiligo antigens. Moab TA99, HMSA-5, and TMH-1 (all directed to the 75 kD tyrosinase-related protein [TRP1]) co-migrated with VIT 75. Moab W6/32 (directed to class I HLA antigen) co-migrated with VIT 40. Immunodepletion studies with vitiligo antibodies selectively depleted the antigen defined by W6/32 but not the antigen defined by TA99 and HMSA-5, indicating that VIT 75 was not the 75 kD tyrosinase-related protein. The vitiligo antigens were easily labelled by the lactoperoxidase technique but poorly labelled with35 S-methionine, suggesting they are expressed on the cell surface. These studies indicate that VIT 90 and VIT 75 differ from antigens defined by currently available moabs to pigment cell antigens. VIT 40 appears to share a cross-reactive epitope, or be tightly bound to, class I HLA antigen. [ABSTRACT FROM AUTHOR]- Published
- 1995
- Full Text
- View/download PDF
20. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo.
- Author
-
Applebaum, Jason, Reynolds, Sandra, Knispel, Jeff, Oratz, Ruth, Shapiro, Richard, Bystryn, Jean-Claude, Applebaum, J, Reynolds, S, Knispel, J, Oratz, R, Shapiro, R, and Bystryn, J C
- Subjects
MELANOMA ,VACCINE biotechnology ,IMMUNOLOGY ,COMPARATIVE studies ,IMMUNOGLOBULINS ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,SKIN tumors ,TUMOR antigens ,CANCER vaccines ,EVALUATION research - Abstract
Background: In the development of an antimelanoma vaccine, a critical factor is the identification of antigens that induce a strong immune response in humans and that are expressed by melanoma cells in vivo. The aim of this study was to identify candidate antigens for such vaccine.Methods: Sixty-nine patients with surgically resected melanomas (American Joint Commission on Cancer [AJCC] stage III) were immunized with a polyvalent vaccine containing multiple melanoma antigens. Antimelanoma antibodies generated in the patients' sera were used as probes to identify the melanoma antigens that are immunogenic in humans and that are expressed on the tumor tissue in vivo. Such responses were determined by an immunoblotting assay that employed an antigen source prepared from membrane fractions of freshly excised melanoma tissue.Results and Conclusions: Vaccine treatment stimulated antibody responses in 35 (51%; 95% confidence interval [CI] = 39%-63%) of 69 sequentially enrolled patients. The antibodies were directed to one or more antigens with molecular masses of 45, 59, 68, 79, 89, 95, and/or 110 kd. The most immunogenic antigens were p110 and p68, which induced responses in 33% (95% CI = 22%-44%) and 25% (95% CI = 15%-35%) of patients, respectively. Both antigens were commonly expressed on different melanomas, but they were absent on autologous normal tissue and on an unrelated allogeneic tumor. All the above antigens are attractive candidates for vaccine construction. [ABSTRACT FROM AUTHOR]- Published
- 1998
- Full Text
- View/download PDF
21. Immunosurveillance and Melanoma.
- Author
-
Bystryn, Jean-Claude
- Subjects
- *
MELANOMA , *VACCINES , *AUGMENTATION mammaplasty , *IMMUNITY , *IMMUNOLOGY , *PREVENTIVE medicine - Abstract
There is considerable indirect and some direct evidence that immune mechanisms can play an important role in controlling the growth of melanoma. In mice, melanoma can be prevented with vaccines. Consequently, even though naturally occurring immunosurveillance may not be sufficiently potent to prevent melanoma, it is possible that the prophylactic augmentation of immunity to melanoma with vaccines may eventually permit this cancer to be prevented in humans. [ABSTRACT FROM AUTHOR]
- Published
- 1989
- Full Text
- View/download PDF
22. An Alternate Explanation for the Increase in the Incidence of Melanoma Being Restricted to Patients With Thin Lesions.
- Author
-
Bystryn, Jean-Claude
- Subjects
MELANOMA ,PRECANCEROUS conditions - Abstract
Argues that a dichotomy exists between the increase in incidence of thin melanomas and the stable incidence of thicker lesions. Mathematical analysis of the differing impacts of the increase in incidence of melanoma and early detection on the proportion of patients who will have thin as opposed to thick lesions at diagnosis.
- Published
- 2000
- Full Text
- View/download PDF
23. CDKN2A Mutations in Multiple Primary Melanomas.
- Author
-
Bystryn, Jean-Claude
- Subjects
- *
LETTERS to the editor , *MELANOMA - Abstract
A letter to the editor is presented in response to the article "CDKN2A Mutations in Multiple Primary Melanomas," by Jose Monson, Ling Liu, Herbert Brill, Alisa M. Goldstein, Margaret A. Tucker, Lynn From, John McLaughlin, David Hogg, and Norman J. Lassam in the March 26, 1998 issue.
- Published
- 1998
- Full Text
- View/download PDF
24. Vitiligo Antigen in Melanoma Cells.
- Author
-
Naughton, Gail K., Lipkin, George, and Bystryn, Jean-Claude
- Subjects
- *
LETTERS to the editor , *MELANOMA - Abstract
Presents a letter to the editor related to melanoma cells, published in the February 1986 issue of the "The Journal of Investigative Dermatology."
- Published
- 1986
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.